Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma
Molecularly targeted therapy and immunotherapy are changing the treatment landscape of soft tissue sarcoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical need for decades. A single oncogenic fusion gene is associated with treatment resistance and a 40 to 45% decrease in overall survival. We previously showed that expression of this PAX3:FOXO1 fusion oncogene in alveolar RMS (aRMS) mediates tolerance to chemotherapy and radiotherapy and that the class I–specific histone deacetylase (HDAC) inhibitor entinostat reduces PAX3:FOXO1 protein abundance. Here, we established the antitumor efficacy of entinostat with chemotherapy in various preclinical cell and mouse models and fou...
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Bharathy, N., Berlow, N. E., Wang, E., Abraham, J., Settelmeyer, T. P., Hooper, J. E., Svalina, M. N., Ishikawa, Y., Zientek, K., Bajwa, Z., Goros, M. W., Hernandez, B. S., Wolff, J. E., Rudek, M. A., Xu, L., Anders, N. M., Pal, R., Harrold, A. P., Davies Tags: STKE Research Articles Source Type: news
Efficacy of Trabectedin in Elderly Patients With Sarcoma Efficacy of Trabectedin in Elderly Patients With Sarcoma
Elderly patients with good performance status benefit from trabectedin for soft tissue sarcoma similarly to younger patients.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma
Trabectedin and eribulin are showing promise for the treatment of soft tissue sarcoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Big, Fat Tumors: Liposarcomas Can Top 70 Pounds
Sarcomas in the soft tissues (such as fat, nerves, ligaments, muscles) of all types are rare, accounting for less than 1% of all malignant tumors in adults. In 2018, the American Cancer Society estimates, about 13,000 new soft-tissue sarcomas of all types will be diagnosed, and about 5,000 Americans will die of them. (Source: WebMD Health)
Source: WebMD Health - October 5, 2018 Category: Consumer Health News Source Type: news
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
TAIPEI, Taiwan, June 21, 2018 -- (Healthcare Sales & Marketing Network) -- PharmaEngine Inc. (TWO: 4162) and its corporate partner, Nanobiotix S.A. (Euronext: NANO) announced today that PEP503 (NBTXR3) in combination with radiotherapy met the primary endp... Biopharmaceuticals, Oncology PharmaEngine, Nanobiotix, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 22, 2018 Category: Pharmaceuticals Source Type: news
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient, Doxil, Velcade and Benlysta
LOS ANGELES, May 3, 2018 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Oncology, Personnel CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 3, 2018 Category: Pharmaceuticals Source Type: news
Crizotinib: New Standard for ALK+ Myofibroblastic Tumor Crizotinib: New Standard for ALK+ Myofibroblastic Tumor
With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor -- a very rare type of soft tissue sarcoma -- crizotinib should be the standard of care, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adult Soft Tissue Sarcoma
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 29, 2018 Category: General Medicine Source Type: news
First-Line Doxorubicin for Advanced Sarcoma, Not Combo? First-Line Doxorubicin for Advanced Sarcoma, Not Combo?
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news
NantCell takes on troubled CytRx chemotherapeutic
NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug.
The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in a significant way compared to a control therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post NantCell takes on troubled CytRx chemotherapeutic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Drug-Device Combinations Mergers & Acquisitions Oncology Pharmaceuticals Wall Street Beat cytrx nantcell Source Type: news
Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin. (Source: CancerNetwork)
Source: CancerNetwork - July 22, 2017 Category: Cancer & Oncology Authors: Sant P. Chawla, MD Tags: Sarcoma Source Type: news
Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news
Coughing and constipation? You could be suffering from THIS rare whole-body cancer
COUGHING and constipation are two of the symptoms of soft tissue sarcomas - a group of rare cancers that can appear anywhere in the body. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2017 Category: Consumer Health News Source Type: news
